Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET
Company Participants
Todd Davis - CEO
Tavo Espinoza - CFO
Paul Hadden - Senior Vice President of Investments and Business Development
Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy
Conference Call Participants
Matt Hewitt - Craig-Hallum
Douglas Miehm - RBC Capital Markets
Lawrence Solow - CJS
Operator
Thank you for standing by. My name is Pam and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand Second Quarter 2024 Earnings Webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you. I would now like to turn the call over to Tavo Espinoza, the Chief Financial Officer of Ligand Pharmaceuticals Inc. You may begin.
Tavo Espinoza
Good afternoon everyone, and welcome to Ligand's second quarter earnings call. During the call today, we will review the financial results we released after today's market close and offer commentary on our partnered pipeline and business development activities, followed by a question-and-answer session.
Our earnings release and a link to today's webcast can be found in the Investor Relations section of our website at ligand.com. With me on the call today our CEO, Todd Davis; Senior Vice President of Investments and Business Development, Paul Hadden and Senior Vice President of Investment and Head of Clinical Strategy, Dr. Karen Reeves.
This call is being recorded, and the audio portion will be archived in the Investors section of our website. On today's call, we will make forward-looking statements regarding our financial results and other matters related to the company's business. Please refer to this safe harbor statement related to these forward-looking statements, which are subject to risks and uncertainties. We remind you that actual events or results may differ materially from those projected or discussed and that all forward-looking statements are based upon current available information. Ligand serves no obligation to update these statements.
To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Ligand filed with the Securities and Exchange Commission that can be found on Ligand's website at www.ligand.com or on the SEC's website at www.sec.gov.
With that, I will now turn the call over to Todd.